CA2635269A1 - Adipogenic adenoviruses as a biomarker for disease - Google Patents
Adipogenic adenoviruses as a biomarker for disease Download PDFInfo
- Publication number
- CA2635269A1 CA2635269A1 CA002635269A CA2635269A CA2635269A1 CA 2635269 A1 CA2635269 A1 CA 2635269A1 CA 002635269 A CA002635269 A CA 002635269A CA 2635269 A CA2635269 A CA 2635269A CA 2635269 A1 CA2635269 A1 CA 2635269A1
- Authority
- CA
- Canada
- Prior art keywords
- adenovirus
- subject
- adipogenic
- sample
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000002293 adipogenic effect Effects 0.000 title claims abstract description 20
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract 23
- 201000010099 disease Diseases 0.000 title claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 8
- 239000000090 biomarker Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 11
- 201000011510 cancer Diseases 0.000 claims abstract 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract 3
- 210000000481 breast Anatomy 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims 28
- 239000000523 sample Substances 0.000 claims 12
- 230000004064 dysfunction Effects 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 4
- 238000012216 screening Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 229940021704 adenovirus vaccine Drugs 0.000 claims 3
- 230000000390 anti-adipogenic effect Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 101710132601 Capsid protein Proteins 0.000 claims 2
- 101710094648 Coat protein Proteins 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 2
- 241001135569 Human adenovirus 5 Species 0.000 claims 2
- 241000509400 Human adenovirus D37 Species 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 101710141454 Nucleoprotein Proteins 0.000 claims 2
- 208000016222 Pancreatic disease Diseases 0.000 claims 2
- 101710083689 Probable capsid protein Proteins 0.000 claims 2
- 241001072909 Salvia Species 0.000 claims 2
- 235000017276 Salvia Nutrition 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 210000000133 brain stem Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 210000003608 fece Anatomy 0.000 claims 2
- -1 feces Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000000653 nervous system Anatomy 0.000 claims 2
- 238000006386 neutralization reaction Methods 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 101710199711 Early E1A protein Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 abstract 2
- 235000020824 obesity Nutrition 0.000 abstract 2
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/075—Adenoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75340205P | 2005-12-27 | 2005-12-27 | |
| US60/753,402 | 2005-12-27 | ||
| PCT/US2006/062632 WO2007120362A2 (en) | 2005-12-27 | 2006-12-27 | Adipogenic adenoviruses as a biomarker for disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2635269A1 true CA2635269A1 (en) | 2007-10-25 |
Family
ID=38610014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002635269A Abandoned CA2635269A1 (en) | 2005-12-27 | 2006-12-27 | Adipogenic adenoviruses as a biomarker for disease |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US7442511B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1977009B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009521707A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080114683A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101389768B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006342053A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0620755A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2635269A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008008453A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2008130893A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007120362A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7507418B2 (en) * | 2005-09-09 | 2009-03-24 | Obetech, Llc | Adenovirus status as a predictor of body composition change, disease status, and treatment outcomes |
| CA2635269A1 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
| US20120082659A1 (en) * | 2007-10-02 | 2012-04-05 | Hartmut Land | Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations |
| JP2009156254A (ja) * | 2007-12-05 | 2009-07-16 | Ibiden Co Ltd | 排気ガス処理体の保持シール部材及び排気ガス処理装置 |
| KR101208778B1 (ko) | 2008-03-03 | 2012-12-05 | 노파르티스 아게 | Ｔｌｒ 활성 조정제로서의 화합물 및 조성물 |
| WO2010011440A2 (en) * | 2008-06-16 | 2010-01-28 | Obetech Llc | Diagnosis and treatment of lipogenic adenovirus infection associated with adipose tissue hypertrophy |
| WO2010144734A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| CN102844047B (zh) | 2009-09-02 | 2017-04-05 | 诺华股份有限公司 | 含tlr活性调节剂的免疫原性组合物 |
| WO2011050299A2 (en) * | 2009-10-22 | 2011-04-28 | Obetech Llc | Adenovirus infection in animals |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| US8585588B2 (en) | 2009-11-18 | 2013-11-19 | Nohands, Llc | Method and system for preventing virus-related obesity and obesity related diseases |
| CN102762206A (zh) | 2009-12-15 | 2012-10-31 | 诺华有限公司 | 免疫增强化合物的均匀悬液及其用途 |
| CA2792938C (en) | 2010-03-23 | 2018-07-31 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| US20130052635A1 (en) * | 2010-03-25 | 2013-02-28 | Richard L. Atkinson | Method For Detecting Lipogenic Adenovirus |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| WO2012006512A1 (en) * | 2010-07-08 | 2012-01-12 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease |
| US20130178517A1 (en) * | 2010-07-09 | 2013-07-11 | Richard L. Atkinson | Methods And Compositions For Treatment Of Lipogenic Virus Related Conditions |
| WO2012083302A2 (en) | 2010-12-17 | 2012-06-21 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
| CN105188747A (zh) | 2013-02-01 | 2015-12-23 | 葛兰素史密斯克莱生物公司 | 包含toll样受体激动剂的免疫组合物的皮内递送 |
| WO2016073773A1 (en) | 2014-11-05 | 2016-05-12 | The United States Of America As Represented By The Secretary Of The Navy | Synthetic antigen constructs against campylobacter jejuni |
| DK3752182T3 (da) | 2018-02-12 | 2024-08-12 | Inimmune Corp | Toll-like receptor ligands |
| EP3861348A4 (en) * | 2018-10-05 | 2022-07-20 | Minomic International Ltd. | BIOMARKER COMBINATIONS FOR DETERMINING AGGRESSIVE PROSTATE CANCER |
| EP4240843A1 (en) | 2020-11-04 | 2023-09-13 | Eligo Bioscience | Cutibacterium acnes recombinant phages, method of production and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE386800T1 (de) * | 1993-03-17 | 2008-03-15 | Us Gov Health & Human Serv | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten |
| WO1998044946A1 (en) | 1997-04-04 | 1998-10-15 | Obetech, Llc | Viral obesity methods and compositions |
| JP2000072800A (ja) * | 1998-08-26 | 2000-03-07 | Toagosei Co Ltd | 抗アデノウイルス３７型モノクローナル抗体及びその用途 |
| US8008436B2 (en) * | 2005-11-30 | 2011-08-30 | Wayne State Univeristy | Adenovirus 36 E4 orf 1 gene and protein and their uses |
| CA2635269A1 (en) * | 2005-12-27 | 2007-10-25 | Obetech, Llc | Adipogenic adenoviruses as a biomarker for disease |
-
2006
- 2006-12-27 CA CA002635269A patent/CA2635269A1/en not_active Abandoned
- 2006-12-27 EP EP06851054.4A patent/EP1977009B1/en active Active
- 2006-12-27 KR KR1020087018439A patent/KR20080114683A/ko not_active Ceased
- 2006-12-27 WO PCT/US2006/062632 patent/WO2007120362A2/en not_active Ceased
- 2006-12-27 BR BRPI0620755-3A patent/BRPI0620755A2/pt not_active Application Discontinuation
- 2006-12-27 CN CN200680053371.XA patent/CN101389768B/zh not_active Expired - Fee Related
- 2006-12-27 EP EP11176754A patent/EP2390372A1/en not_active Withdrawn
- 2006-12-27 US US11/616,799 patent/US7442511B2/en not_active Expired - Fee Related
- 2006-12-27 RU RU2008130893/13A patent/RU2008130893A/ru not_active Application Discontinuation
- 2006-12-27 JP JP2008548837A patent/JP2009521707A/ja active Pending
- 2006-12-27 AU AU2006342053A patent/AU2006342053A1/en not_active Abandoned
- 2006-12-27 MX MX2008008453A patent/MX2008008453A/es active IP Right Grant
-
2008
- 2008-10-24 US US12/257,967 patent/US7910310B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/257,937 patent/US7745110B2/en not_active Expired - Fee Related
-
2011
- 2011-02-07 US US13/022,219 patent/US20110189235A1/en not_active Abandoned
-
2013
- 2013-08-14 US US13/966,631 patent/US20130323273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20070218081A1 (en) | 2007-09-20 |
| EP1977009B1 (en) | 2016-08-17 |
| US20090087455A1 (en) | 2009-04-02 |
| US20110189235A1 (en) | 2011-08-04 |
| WO2007120362A3 (en) | 2008-08-14 |
| US7442511B2 (en) | 2008-10-28 |
| EP1977009A4 (en) | 2009-06-03 |
| US20090087833A1 (en) | 2009-04-02 |
| US7910310B2 (en) | 2011-03-22 |
| RU2008130893A (ru) | 2010-02-10 |
| US20130323273A1 (en) | 2013-12-05 |
| WO2007120362A2 (en) | 2007-10-25 |
| EP1977009A2 (en) | 2008-10-08 |
| AU2006342053A1 (en) | 2007-10-25 |
| KR20080114683A (ko) | 2008-12-31 |
| CN101389768A (zh) | 2009-03-18 |
| BRPI0620755A2 (pt) | 2011-11-22 |
| JP2009521707A (ja) | 2009-06-04 |
| EP2390372A1 (en) | 2011-11-30 |
| MX2008008453A (es) | 2008-11-28 |
| CN101389768B (zh) | 2015-11-25 |
| US7745110B2 (en) | 2010-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2635269A1 (en) | Adipogenic adenoviruses as a biomarker for disease | |
| Filmus et al. | Glypican‐3: a marker and a therapeutic target in hepatocellular carcinoma | |
| CN102171570B (zh) | 用于检测癌的方法 | |
| JP4917207B2 (ja) | 前立腺疾患の検出に有用な試薬及び方法 | |
| KR101872965B1 (ko) | Ｃ―ｍａｆ를 이용하는 전립선암 전이의 진단, 예후 및 치료 방법 | |
| JP2010246558A (ja) | 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法 | |
| JP2011092195A (ja) | 卵巣癌の同定、評価、予防および治療のための核酸分子およびタンパク質 | |
| JP2006201187A (ja) | 前立腺ガンの免疫診断のための化合物およびそれらの使用方法 | |
| JP2001503980A (ja) | 乳房の疾患の検出に有用な試薬および方法 | |
| PT1994410E (pt) | Métodos e estojos para detecção precoce de cancro ou de predisposição a este | |
| JP2009544284A5 (cg-RX-API-DMAC7.html) | ||
| JP2008509673A (ja) | ヒト前立腺癌の同定、評価、予防および治療のための遺伝子、組成物、キットおよび方法 | |
| JP5773315B2 (ja) | 膵癌のバイオマーカーとしてのｃｘｃｌ４ｌ１ | |
| JP2001521744A (ja) | 乳房の疾患の検出に有用な試薬および方法 | |
| CN109517898B (zh) | 一种食管癌检测、诊断或者预后评价制剂，治疗食管癌的药物及rnd2基因的应用 | |
| JP2001522238A (ja) | 胃腸管の疾患の検出に有用な試薬および方法 | |
| JP2012513584A5 (cg-RX-API-DMAC7.html) | ||
| KR102180982B1 (ko) | 갑상선암 진단 또는 예후 예측용 adm2 유전자 마커 및 이의 용도 | |
| KR20070073802A (ko) | Ｗｎｔ 단백질 및 암의 검출 및 치료 | |
| JP2002503956A (ja) | 前立腺の疾患の検出に有用な試薬および方法 | |
| JP2017526896A (ja) | 補体因子ｂタンパク質に特異的に結合する抗体及び糖鎖抗原１９−９タンパク質に特異的に結合する抗体を含む膵臓癌診断用キット | |
| KR20220020538A (ko) | 전립선암 진단용 마커 | |
| JP2022521535A (ja) | 前立腺がんのバイオマーカとしてのｂｍｍｆ１ ｒｅｐタンパク質の使用 | |
| Miehlke et al. | Expression of G1 phase cyclins in human gastric cancer and gastric mucosa of first-degree relatives | |
| KR101314959B1 (ko) | 결장직장선종 및/또는 결장직장암종에 대한 생체표지로서엔도플라스민 단편 및 그 유도체의 사용； 검출 방법 및시험 시스템 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20171228 |